The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder
The company is working closely with its six manufacturing partners in India
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Essential medicines were made available to more than 150 countries around the world during the pandemic
Subscribe To Our Newsletter & Stay Updated
